ArticleBMC cancer2023
Clinical features and prognosis of cardiac metastatic tumors.
Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Cardiac metastases from colorectal cancer: a comprehensive systematic review of clinical presentation, cardiac involvement, and outcomes.Clinical & experimental metastasis · 2026Pooled it
- Inferior STEMI in a Patient With Cardiac Metastasis: A Diagnostic Challenge.JACC. Case reports · 2026Article
- Metastatic Soft Tissue Sarcoma With Cardiac Involvement: A Case Study on the Role of Multimodal Imaging in Diagnosis and Management.Clinical case reports · 2026Article
- Tricuspid valve metastasis and tumoural pulmonary embolism case report: a rare germ cell tumour manifestation.European heart journal. Case reports · 2026Article
- Complete Heart Block and Massive Pericardial Effusion as the Presenting Manifestations of Metastatic Colorectal Adenocarcinoma.JACC. Case reports · 2026Article
- Article
- Cardiac Papillary Fibroelastoma as a Cause of Sudden Cardiac Arrest.JACC. Case reports · 2026Article
- Multimodal echocardiographic techniques in the diagnosis of cardiac tumors: applications and recent advances.Frontiers in cardiovascular medicine · 2026Review
- Progression of intracardiac metastases from gastroenteropancreatic neuroendocrine tumors.Nuclear medicine communications · 2026Article
- Cardio-immuno-oncology in cardiac tumors and cardiac metastases: immune microenvironment, therapeutic opportunities, and cardiotoxicity.Frontiers in immunology · 2026Review
- Dual Left Atrial Masses Causing Inflow Obstruction: A Rare Presentation of Primary Cardiac Intimal Sarcoma.Vascular health and risk management · 2026Article
- An Unusual Presentation of Metastatic Soft Tissue Sarcoma to the Left Atrium and Pulmonary Veins: A Case Report and Comprehensive Literature Review.Clinical case reports · 2025Article
- Review
- Extensive Right Ventricular Involvement With Thrombus and Myocarditis: An Unanticipated Discovery in Advanced Hepatocellular Carcinoma.JACC. Case reports · 2025Article
- Primary Cardiac Tumors: Clinical Presentations and Pathological Features in a Multicenter Cohort.Diagnostics (Basel, Switzerland) · 2025Article
- Cardiac Metastasis of Pulmonary Spindle Cell Carcinoma Mimicking Lateral ST-Segment Elevation Myocardial Infarction.JACC. Case reports · 2025Article
- Article
- Cardiac Metastasis: Epidemiology, Pathophysiology, and Clinical Management.Life (Basel, Switzerland) · 2025Review
- Bridging the gap in cardiac mass diagnosis: Advanced imaging, genetic associations, and biomarkers.World journal of clinical cases · 2024Article
- Case Report: Lung cancer with rare cardiac and other multiple metastases.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThis study aimed to explore the clinical features and prognosis of cardiac metastatic tumors. In addition, whether continuing antitumor therapy after the development of cardiac metastases can benefit patients and the response of cardiac metastases were investigated.
methodsA retrospective analysis was conducted on patients with malignancies who were admitted to Fujian Cancer Hospital and Fujian Provincial Hospital from January 2007 to September 2022, and the follow-up period ended in March 2023. Clinical data were gathered, treatment efficacy was evaluated, and survival analysis was performed.
resultsAfter the patients developed cardiac metastasis, the overall 30-day, 3-month, 6-month, and 12-month survival rates were 85.00%, 59.00%, 51.00% and 38.00%, respectively. With continued treatment, the average survival time was 27.33 months (95% confidence interval [CI]: 16.88-37.79), which exceeded the 6.6 months (95% confidence interval [CI]: 0.03-13.69) observed for patients who withdrew from treatment (P < 0.001). The responses of cardiac metastases corresponded to the responses of the primary tumors. Patients with a cardiac response had a median survival time of 55.60 months, which exceeded the 13.40 months observed for those without a cardiac response. However, there was no significant difference (P = 0.375).
conclusionsIn conclusion, continuing antitumor therapy after the development of cardiac metastases can significantly prolong patient survival. Cardiac metastases and primary tumors respond consistently to antitumor treatment. The risk of death due to heart failure in cancer patients with cardiac metastases needs to be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.